Moderna stock rating reiterated at Buy by Brookline Capital Markets

Investing.com - Brookline Capital Markets has reiterated a Buy rating on Moderna (NASDAQ:MRNA) with a price target of $198.00 following FDA approval of the company’s COVID-19 vaccine for younger children. The stock, currently trading at $33.85, has shown strong momentum with a 7.5% gain over the past week, though it remains significantly below its 52-week high of $129.39. According to InvestingPro analysis, Moderna appears undervalued based on its Fair Value metrics.

The FDA approved Moderna’s Spikevax for children 6 months through 11 years of age with underlying conditions, expanding on its previous approval for individuals 12 years and older. This approval follows the FDA’s May 2025 authorization of Moderna’s new COVID-19 vaccine, mNEXSPIKE (mRNA-1283), for adults 65 and older and individuals aged 12-64 years with risk factors. While the company maintains a strong liquidity position with a current ratio of 4.22 and more cash than debt on its balance sheet, InvestingPro data reveals the company is currently experiencing accelerated cash burn.

Brookline Capital Markets estimates Moderna will sell approximately 10.9 million COVID-19 vaccine doses in the US during 2025, down from an estimated 14.6 million doses in 2024. The firm projects global COVID-19 vaccine sales could reach $2.4 billion in 2025.

Looking further ahead, Brookline forecasts Moderna’s COVID-19 vaccine sales could grow to $15.6 billion by 2030, indicating long-term growth potential for the company’s vaccine business.

Beyond its standalone COVID-19 vaccines, Moderna is developing mRNA1083, a combination COVID-19 and flu vaccine primarily targeted at older adults, further expanding its respiratory vaccine portfolio. With the next earnings report due on July 31, investors can access comprehensive analysis and 14 additional ProTips through InvestingPro’s detailed research reports.

In other recent news, Moderna has reported positive results from a Phase 3 trial of its mRNA-1010 seasonal influenza vaccine, demonstrating a 26.6% higher efficacy compared to standard-dose flu vaccines in adults aged 50 and older. The study, which involved 40,805 participants across 11 countries, showed strong efficacy across all influenza strains, with the company planning to present these findings at an upcoming medical conference and engage with regulators for filing submissions. Meanwhile, William Blair has reiterated its Market Perform rating on Moderna following these positive developments, citing the potential for regulatory approval of the mRNA-1010 and mRNA-1083 vaccines. In legal matters, Pfizer (NYSE:PFE) and BioNTech (NASDAQ:BNTX) are appealing a UK court ruling that found their COVID-19 vaccine infringed on one of Moderna’s mRNA patents, a case that continues to unfold in London’s Court of Appeal. Additionally, Health and Human Services Secretary Robert F. Kennedy has reshuffled the Advisory Committee for Immunization Practices, appointing eight new members with diverse expertise in vaccine safety, mRNA technology, and healthcare analytics. This committee will review safety and efficacy data for new vaccine recommendations and the current vaccination schedule. These developments reflect ongoing advancements and challenges in the vaccine industry.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.